Cargando…
Post-trial access to treatment for patients participating in clinical trials
Clinical trials are the mainstay for bringing out newer and better drugs to serve the mankind. By virtue of participating in a clinical trial, a patient receives access to the newer drugs/therapies, but nothing is generally being offered to them once their participation in the study comes to an end....
Autores principales: | Doval, Dinesh Chandra, Shirali, Rashmi, Sinha, Rupal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394585/ https://www.ncbi.nlm.nih.gov/pubmed/25878952 http://dx.doi.org/10.4103/2229-3485.154003 |
Ejemplares similares
-
Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma
por: Doval, Dinesh Chandra, et al.
Publicado: (2014) -
Post-trial access
por: Usharani, Pingali, et al.
Publicado: (2013) -
A rare case of brain metastasis in a patient with osteosarcoma
por: Doval, Dinesh Chandra, et al.
Publicado: (2017) -
Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
por: Doval, D. C., et al.
Publicado: (2013) -
Elderly patients’ participation in clinical trials
por: Shenoy, Premnath, et al.
Publicado: (2015)